Clinical trials: Tamoxifen
Systemic Mastocytosis
Use of Tamoxifen in Systemic Mastocytosis
In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic agent, to improve quality of life, biochemical parameters, and bone marrow involvement in systemic mastocytosis patients having 1) up to…
- Trial name
- NCT01334996
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Breast Cancer
Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking use of estrogen by the tumor cells.
- Trial name
- NCT00541086
- Testing
- anastrozole, exemestane, letrozole
- Where
- 5 sites in Italy
- Volunteers
- 3,697 people
- Sponsor
- Gruppo Italiano Mammella (GIM)
Breast Cancer, Early-stage Breast Cancer
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
In this research study, investigators are testing if a dose-increasing strategy for abemaciclib will have less side effects and be better tolerated than the standard dosage of abemaciclib for participants with early-stage…
- Conditions
- Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
- Trial name
- NCT06001762
- Testing
- Abemaciclib, Tamoxifen, Anastrozole
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
The aim of the study is to investigate the efficacy of different dosing and scheduling of Nolvadex in preventing gynecomastia/mastalgia induced by Casodex 150 mg monotherapy in patients with prostate cancer.
- Trial name
- NCT00233610
- Testing
- Bicalutamide, Tamoxifen
- Where
- 11 sites in Italy
- Volunteers
- 180 people
- Sponsor
- AstraZeneca
Breast Neoplasms
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.
- Trial name
- NCT00229697
- Testing
- Gefitinib, Tamoxifen
- Where
- 55 sites in United States, Argentina and 10 more
- Volunteers
- 317 people
- Sponsor
- AstraZeneca
Breast Cancer
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
The purpose of this study is to determine the safety and tolerability of the combination of two drugs (letrozole and leuprolide) in women who have already taken tamoxifen for at least 4.5 years.
- Trial name
- NCT00903162
- Testing
- leuprolide, letrozole, zoledronic acid
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer
This is a pilot, prospective, interventional, monocentric study designed to evaluate, in a real-life situation, adherence to tamoxifen treatment as a function of the taking of alternative and complementary therapies in patients…
- Trial name
- EUTACAM (NCT04740697)
- Testing
- Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Claudius Regaud
Breast Cancer, HER2-negative Breast Cancer
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
- Trial name
- NCT05150652
- Testing
- Anastrozole 1mg, Letrozole 2.5mg, Exemestane 25 mg
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Irada Ibrahim-zada
Osteoporosis, Postmenopausal, Osteoporosis
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
Osteoporosis remains a significant healthcare burden for the United States. Current FDA-approved osteoporosis treatments include teriparatide, abaloparatide, bisphosphonates, denosumab, and raloxifene.
- Trial name
- NCT03623633
- Testing
- denosumab, alendronate, raloxifene
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Endometrial Receptivity Post Tamoxifen Exposure
Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients
The aim of this multi-center study is to assess the effects of Tamoxifen on the uterine cavity and endometrial abnormalities in young premenopausal women diagnosed with breast cancer.
- Trial name
- NCT02311647
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Sheba Medical Center
Non Small Cell Lung Cancer, Solid Tumors
Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma
This is an open label trial for patients currently enrolled in other perifosine trials.
- Conditions
- Non Small Cell Lung Cancer, Solid Tumors, Metastatic Breast Cancer, Sarcomas
- Trial name
- NCT00847366
- Testing
- Perifosine, Trastuzumab, Tamoxifen
- Volunteers
- 10 people
- Sponsor
- AEterna Zentaris
Breast Neoplasms
German Preoperative Adriamycin Docetaxel Study
The primary objective of this trial is to determine the rate of pathologically complete remissions following a preoperative dose-intensified therapy with doxorubicin and docetaxel with or without tamoxifen in patients with…
- Trial name
- NCT00543829
- Testing
- doxorubicin, docetaxel, tamoxifen, doxorubicin, docetaxel
- Volunteers
- 250 people
- Sponsor
- GBG Forschungs GmbH
HR+/HER2-breast Cancer
A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer
This is a randomized, controlled, open, phase III trial of adjuvant intensive therapy for early breast cancer with HR+/ HER2-SNF4 based on SNF molecular typing.
- Trial name
- NCT05889871
- Testing
- Standard endocrine therapy plus Apatinib
- Volunteers
- 916 people
- Sponsor
- Fudan University
Breast Cancer
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone…
- Trial name
- EarLEE-2 (NCT03081234)
- Testing
- Ribociclib, Adjuvant endocrine therapy
- Sponsor
- Novartis Pharmaceuticals
ER-positive Breast Cancer, HER2-negative Breast Cancer
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
This is an international, multi-center, randomised, open label, superiority phase III trial of elacestrant vs standard endocrine therapy in patients with ER+/HER2- breast cancer and ctDNA relapse.
- Conditions
- ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
- Trial name
- TREAT ctDNA (NCT05512364)
- Testing
- Elacestrant, Tamoxifen, Letrozole 2.5mg
- Where
- 113 sites in Belgium, Cyprus and 10 more
- Volunteers
- 220 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
This phase II trial studies how well giving combination chemotherapy and peripheral blood stem cell transplant followed by aldesleukin and sargramostim works in treating patients with inflammatory stage IIIB or metastatic stage…
- Conditions
- Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer
- Trial name
- NCT00003199
- Testing
- tamoxifen citrate, busulfan, thiotepa
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer, Osteoporosis
An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice
The aim of this study is to determine the effect of aromatase inhibitors therapy on bone mineral density and compare it to the effects of tamoxifen and no hormonal therapy.
- Trial name
- NCT00767585
- Where
- Slovenia
- Volunteers
- 560 people
- Sponsor
- AstraZeneca
Breast Cancer
Evaluating the Response-Guided Therapy With Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer (JCOG2402, Young HOPE)
Young HOPE/JCOG2402 is a multicenter, randomized phase III study designed to evaluate response-guided therapy following neoadjuvant endocrine therapy to optimize adjuvant treatment in premenopausal HR+/HER2- Breast Cancer.
- Trial name
- YoungHOPE (NCT07671885)
- Testing
- Adjuvant systemic therapy based on pathological findings and ET response, Adjuvant systemic therapy based on pathological findings
- Where
- 49 sites in Japan
- Volunteers
- 950 people
- Sponsor
- Tokyo Women's Medical University
Breast Cancer
Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
This study will determine if hormone receptor positive premenopausal metastatic breast cancer patients who undergo removal of the ovaries in mid-luteal versus mid-follicular phase have a longer survival.
- Trial name
- NCT00293540
- Testing
- oophorectomy, Tamoxifen
- Where
- 21 sites in United States, Bangladesh and 8 more
- Volunteers
- 249 people
- Sponsor
- International Breast Cancer Research Foundation
Endometrial Hyperplasia, Endometrial Neoplasms
Correlation Between Hysteroscopic Diagnosis of Endometrial Hyperplasia and Histopathological Examination
A prospective cohort study at a Tertiary University Hospital. From January to December 2018, we enrolled women with the following criteria: abnormal uterine bleeding in post-menopause, endometrial thickening in pre-or…
- Trial name
- NCT03917147
- Testing
- Office Hysteroscopy
- Where
- Italy
- Volunteers
- 435 people
- Sponsor
- University of Campania Luigi Vanvitelli